Evaluation of Pre-Exposure Prophylaxis for High Risk Adolescent Girls and Young Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1032 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-25

Study Completion Date

2020-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To provide preliminary evidence about feasibility and acceptability of delivering PrEP to AGYW identified as potentially at high risk of HIV infection in Lilongwe city communities and two public facilities in Lilongwe, Malawi. The primary objective of the study is to assess the feasibility, acceptability, tolerability and cost of delivering PrEP among high-risk AGYW aged 18-24 years and healthcare providers in urban Lilongwe. Secondary objectives are (i) to assess the program's ability to enroll and retain a PrEP cohort for one year and (ii) measure the incidence of HIV infection among high risk AGYW in urban Lilongwe among women who decline to enroll in the PrEP study (these will be offered enrollment in the HIV incidence study).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi

NCT06200545

HIV Infection Sexually Transmitted Infections Pre-exposure Prophylaxis +1 more

COMPLETED NA

Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe

NCT05307991

HIV Infections Sexually Transmitted Diseases Blood-Borne Infections +9 more

COMPLETED

Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya

NCT04982250

HIV Prevention

COMPLETED NA

Supporting Oral Pre-exposure Prophylaxis Decision Making Among Pregnant Women in Lilongwe, Malawi

NCT06394323

HIV Prevention

COMPLETED NA

Improving Uptake and Adherence to HIV Prevention Services With Pre-exposure Prophylaxis (PrEP), HIV Self- Testing and Adherence Support for Very High Risk HIV-negative Young Women Aged 15-24 in Kampala, Uganda

NCT04030520

HIV/AIDS

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main goal of the study is to provide preliminary evidence about feasibility and acceptability of delivering PrEP to AGYW identified as potentially at high risk of HIV infection in Lilongwe city communities and two public facilities in Lilongwe, Malawi. The primary objectives are to; determine HIV prevalence among all AGYW identified as potentially at high risk of HIV infection in urban Lilongwe; assess the HIV program's ability to enroll and retain the PrEP cohort for one year; assess participants' and providers' perceptions of the barriers and facilitators for providing PrEP to inform implementation of PrEP study and future interventions and assess the cost of PrEP delivery in the routine HIV program.

Secondary Objectives:

1. To measure annual HIV incidence in a prospective cohort of HIV-negative AGYW identified as potentially at high risk of HIV infection but declined to enroll in PrEP cohort study in urban Lilongwe.
2. To measure annual HIV incidence among HIV-negative AGYW who enrolled in PrEP cohort study in urban Lilongwe.
3. To determine risk factors for HIV in a cohort of AGYW recruited in the prospective cohort study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV/AIDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

A non- randomized study design being implemented in 2 facilities in Lilongwe Urban. The first component is a cross-sectional study of AGYW in which HIV testing counselors will offer HIV tests and assess HIV risk. A sample of AGYW testing HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence. In the third component, AGYW who consent will be enrolled in a PrEP study. The PrEP study has two phases, which are, (i) a formative qualitative study involving AGYW and PrEP providers to understand factors and barriers to delivering PrEP to AGYW and (ii) a feasibility study of delivering PrEP to HIV negative AGYW. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PrEP Cohort

AGYW HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.

Group Type EXPERIMENTAL

PrEP Cohort

Intervention Type BEHAVIORAL

AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.

HIV Incidence

HIV Incidence Cohort: In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PrEP Cohort

AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Eligibility criteria for the cross-sectional study

* Female
* Consent to be counselled and tested for HIV
* Between 18 and 24 years old
* Ongoing HIV risk according to the risk Assessment guide
* Participated in the cross-sectional screening study or meets the eligibility criteria for the cross-sectional study
* Willing to provide written informed consent to participate in the HIV incidence study
* Accesses services at a mobile or fixed clinic in the defined catchment area
* Not planning to relocate in the next 12 months Eligibility criteria for the prospective PrEP for AGYW
* Participated in the cross-sectional study
* HIV-negative
* Answers yes to any two questions from the PrEP screening tool
* Willing and able to adhere to daily PrEP
* Willing to provide written informed consent to participate in the PrEP study
* Accesses services at a mobile or fixed clinic in the defined catchment area
* Not planning to relocate in the next 12 months

Eligibility criteria for focus group discussions for PrEP providers

* Provided PrEP for at least 3 months
* Trained nurse
* Orientated in PrEP and study procedures

Exclusion Criteria

• HIV positive

* Under 18 years or older than 24 years at enrollment (including AGYW aged 24 years at enrolment)
* Breastfeeding women
* Already taking oral or injectable PrEP through another study
* Current or past history of renal or liver disease
* Clients on multi-drug resistant tuberculosis (MDR-TB) medications
* Signs of acute HIV infection. The client would be asked to return after 3 months for a re-evaluation
* FSW \<35kg
* Known allergy to tenofovir disoproxil fumarate (TDF) and/or emtricitabine (FTC);
* Unwilling or unable to return for 3-monthly HIV testing, counselling and safety monitoring visits or planning to relocate to another geographic area during the period of the study.
* Blood creatinine clearance (Cr Cl) \<60ml/min

Minimum Eligible Age

18 Years

Maximum Eligible Age

24 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes